Learn how we can build together a resilient path for CM patients and families.

Download the Roadmap here

The Netherlands

Currently, the Netherlands has about 1.7 million people living with cardiovascular disease.1 Cardiovascular diseases are the second leading cause of death and the main reason for hospital admissions in the Netherlands. 2-5

‘Cardiomyopathies are heart muscle diseases affecting about 1 in 500 individuals in the Netherlands, meaning roughly 40,000 people live with cardiomyopathy— around 2.4% of all cardiovascular patients. Both prevalence and disease burden are rising, yet these conditions have received little policy attention so far.6-7

In June 2023, several organizations launched the initiative ‘Zorg voor de Hartspier’ with one central question: “How can we better reach society and improve understanding and support for individuals living with cardiomyopathy?”. The Goal? Reduce disease burden and societal impact for people with inherited heart conditions.

Making the impact visible: The Impact Map

To address this, the initiative aims to improve factual insight into cardiomyopathies in the Netherlands. This includes quantifying disease burden and societal impact through an impact analysis with contributions from the following experts.

Expert contributors

Dayenne Zwaagman – Heart patient, co-founder of Hart4Onderzoek and care improver at Amsterdam UMC Heart center

Prof. Dr. Jolanda van der Velden –Department Head of Physiology at Amsterdam UMC and Scientific director of the Netherlands Heart Institute

Prof. Dr. Maarten Postma – Professor Global Health Economics UMC Groningen

Dr. Rogier Veltrop – Molecular cell biologist at CARIM/Maastricht University, Heart Transplant Recipient and co-founder of LMNAcardiac

Marion van Sinttruije – Heart patient, co-founder of Stichting Cardiomyopathy Research Netherlands

Dr. Diederik Kuster – Assistant professor Physiology Amsterdam UMC

Dr. Job Verdonschot – Clinical Geneticist and Associate Professor Cardiogenetics at Maastricht UMC+

Cardiomyopathies in the Netherlands: key facts, challenges, and opportunities

An at-a-glance overview of the impact of cardiomyopathies in the Netherlands, combining data, insights and expert opinion to quantify disease burden and societal impact.

⬇️ Download the full report here.

References:

  1. https://www.hartstichting.nl/hart-en-vaatziekten/cijfers-hart-en-vaatziekten
  2. Hart- en vaatziekten | Zorguitgaven | Volksgezondheid en Zorg. Accessed December 1, 2023. https://www.vzinfo.nl/hart-en-vaatziekten/zorguitgaven
  3. Jaarcijfers Hart- en Vaatziekten 2021: Hart & Vaatcijfers. Accessed November 30, 2023. https://www.hartenvaatcijfers.nl/jaarcijfers/jaarcijfers-hart-en-vaatziekten-2021-e15f3
  4. Ranglijsten | Wat zijn de belangrijkste doodsoorzaken? | Volksgezondheid en Zorg. Accessed December 4, 2023. https://www.vzinfo.nl/ranglijsten/sterfte
  5. Sterfte naar doodsoorzaak. Accessed December 4, 2023. https://www.cbs.nl/nl-nl/longread/diversen/2022/ontwikkelingen-in-sterfte-in-2020-en-2021/6-sterfte-naar-doodsoorzaak
  6. Hartstichting.nl. 4. Basiscijfers cardiomyopathie: Hart & Vaatcijfers. Accessed November 29, 2023. https://www.hartenvaatcijfers.nl/jaarcijfers/basiscijfers-cardiomyopathie-f54bb
  7. Cardiomyopathies Matter Cardiomyopathies Matter A Policy Roadmap to improve cardiomyopathy detection and care in Europe. Accessed November 30, 2023. www.cardiomyopathiesmatter.org

CV-NL-2500062

Scroll to Top